Monthly Prescribing Reference

Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...
Nasdaq

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi(TM) From the US market

LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announces that the U.S. Food and Drug Administration (FDA) has granted Camurus' US partner Braeburn's request (through ...
Monthly Prescribing Reference

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Braeburn announced that the Food and Drug Administration (FDA) has tentatively approved Brixadi (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe ...
WTNH

Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder

LUND, Sweden, May 24, 2023 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended release injection ...
Business Insider

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

LUND, Sweden, July 23, 2019 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announces that the United States District Court for the District of Columbia grants Braeburn's motion for summary ...
Daily Local News

FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADITM (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

PLYMOUTH MEETING, Pa., June 26, 2021 /PRNewswire/ — Braeburn announces that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous ...
dailyfreeman.com

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

LUND, Sweden, June 26, 2021 /PRNewswire/ — Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus’ US licensee Braeburn for BrixadiTM (buprenorphine) ...